DE2453113C2 - Verwendung von 5-(Hydroxy-3-tert.-butylamino)-propoxy-3,4-dihydro-2-hydroxychinolin zur Verhinderung der Blutplättchenaggregation verhindernden Arzneimittels - Google Patents
Verwendung von 5-(Hydroxy-3-tert.-butylamino)-propoxy-3,4-dihydro-2-hydroxychinolin zur Verhinderung der Blutplättchenaggregation verhindernden ArzneimittelsInfo
- Publication number
- DE2453113C2 DE2453113C2 DE2453113A DE2453113A DE2453113C2 DE 2453113 C2 DE2453113 C2 DE 2453113C2 DE 2453113 A DE2453113 A DE 2453113A DE 2453113 A DE2453113 A DE 2453113A DE 2453113 C2 DE2453113 C2 DE 2453113C2
- Authority
- DE
- Germany
- Prior art keywords
- butylamino
- hydroxy
- hydroxyquinoline
- propoxy
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000010110 spontaneous platelet aggregation Diseases 0.000 title description 3
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 238000004220 aggregation Methods 0.000 description 12
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 11
- 229960001138 acetylsalicylic acid Drugs 0.000 description 11
- 230000002776 aggregation Effects 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 6
- 230000035699 permeability Effects 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- PMZDQRJGMBOQBF-UHFFFAOYSA-N quinolin-4-ol Chemical compound C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP48125930A JPS5082218A (en, 2012) | 1973-11-10 | 1973-11-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2453113A1 DE2453113A1 (de) | 1975-05-15 |
| DE2453113C2 true DE2453113C2 (de) | 1986-10-16 |
Family
ID=14922462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2453113A Expired DE2453113C2 (de) | 1973-11-10 | 1974-11-08 | Verwendung von 5-(Hydroxy-3-tert.-butylamino)-propoxy-3,4-dihydro-2-hydroxychinolin zur Verhinderung der Blutplättchenaggregation verhindernden Arzneimittels |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US3969507A (en, 2012) |
| JP (1) | JPS5082218A (en, 2012) |
| AU (1) | AU472682B2 (en, 2012) |
| CA (1) | CA1034500A (en, 2012) |
| DE (1) | DE2453113C2 (en, 2012) |
| FR (1) | FR2250531B1 (en, 2012) |
| GB (1) | GB1491503A (en, 2012) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH619453A5 (en, 2012) * | 1976-03-17 | 1980-09-30 | Otsuka Pharma Co Ltd | |
| SU843739A3 (ru) * | 1978-02-17 | 1981-06-30 | Карл Томэ Гмбх (Фирма) | Способ получени карбостириловыхили ОКСиНдОлОВыХ пРОизВОдНыХ |
| AU518814B2 (en) * | 1979-01-30 | 1981-10-22 | Otsuka Pharamaceutical Co. | Glaucoma treatment |
| JPS56122356A (en) * | 1980-02-29 | 1981-09-25 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
| US4442111A (en) * | 1981-07-25 | 1984-04-10 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | Antithrombotic sulfimino and sulfoximino indolinones-2 |
| DE3310891A1 (de) * | 1983-03-25 | 1984-09-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
| JPS63290821A (ja) * | 1987-05-25 | 1988-11-28 | Otsuka Pharmaceut Co Ltd | 抗不整脈剤 |
| ES2070151T3 (es) * | 1988-08-10 | 1995-06-01 | Otsuka Pharma Co Ltd | Agentes cardiotonicos. |
| US4949722A (en) * | 1989-09-18 | 1990-08-21 | Roy Bean | Method for determining blood platelet adhesiveness |
| TW201305B (en, 2012) * | 1991-04-03 | 1993-03-01 | Otsuka Pharma Co Ltd | |
| JPH07252153A (ja) * | 1995-01-25 | 1995-10-03 | Otsuka Pharmaceut Co Ltd | 抗不整脈剤 |
| EP1902141B1 (en) * | 2005-06-17 | 2012-02-08 | Baxter International Inc. | Adamts13-comprising compositions having thrombolytic activity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH408006A (de) * | 1962-05-11 | 1966-02-28 | Geigy Ag J R | Verfahren zur Herstellung von Chinolyl-(8)-oxyessigsäurederivaten |
| DE1216878B (de) * | 1963-04-02 | 1966-05-18 | Cassella Farbwerke Mainkur Ag | Verfahren zur Herstellung von coronargefaesserweiternden Derivaten des 7-Hydroxy-2-oxo-1, 2-dihydrochinolins |
| CH528214A (de) * | 1970-02-13 | 1972-09-30 | Ciba Geigy Ag | Schädlingsbekämpfungsmittel |
| JPS48103590A (en, 2012) * | 1972-04-13 | 1973-12-25 |
-
1973
- 1973-11-10 JP JP48125930A patent/JPS5082218A/ja active Pending
-
1974
- 1974-11-05 CA CA212,988A patent/CA1034500A/en not_active Expired
- 1974-11-05 AU AU75066/74A patent/AU472682B2/en not_active Expired
- 1974-11-08 GB GB48520/74A patent/GB1491503A/en not_active Expired
- 1974-11-08 DE DE2453113A patent/DE2453113C2/de not_active Expired
- 1974-11-11 US US05/522,835 patent/US3969507A/en not_active Expired - Lifetime
- 1974-11-12 FR FR7437327A patent/FR2250531B1/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2250531A1 (en, 2012) | 1975-06-06 |
| JPS5082218A (en, 2012) | 1975-07-03 |
| CA1034500A (en) | 1978-07-11 |
| GB1491503A (en) | 1977-11-09 |
| FR2250531B1 (en, 2012) | 1978-06-30 |
| AU7506674A (en) | 1976-06-03 |
| DE2453113A1 (de) | 1975-05-15 |
| US3969507A (en) | 1976-07-13 |
| AU472682B2 (en) | 1976-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2453113C2 (de) | Verwendung von 5-(Hydroxy-3-tert.-butylamino)-propoxy-3,4-dihydro-2-hydroxychinolin zur Verhinderung der Blutplättchenaggregation verhindernden Arzneimittels | |
| DE3152175C2 (en, 2012) | ||
| DE3878790T2 (de) | Organo-anorganische vanadyl-verbindung, verfahren zur herstellung einer solchen verbindung, pharmazeutische zusammensetzung, die diese organo-anorganische verbindung enthaelt. | |
| DE2538424C2 (de) | 4-substituierte 5-Phenyl-oxazolidon-(2)- Verbindungen und ein diese enthaltendes pharmazeutisches Präparat | |
| DE91409T1 (de) | Carrageen enthaltende arzneimittelzusammensetzungen. | |
| DE3311922A1 (de) | Antifibrotische mittel | |
| DE2241470A1 (de) | Arzneimittel mit antivirus-wirksamkeit | |
| DE3852717T2 (de) | Zusammensetzung für die Prophylaxe von Pneumocystis-carinii-Pneumonie. | |
| DE2335729A1 (de) | Vincanolsalze, verfahren zu deren herstellung und diese verbindungen als wirkstoffe enthaltende pharmazeutische zubereitungen | |
| DE3810264C2 (en, 2012) | ||
| DE3011274A1 (de) | Synergistische strahlenschuetzende pharmazeutische praeparate sowie deren herstellung | |
| DE2728589C3 (de) | Verwendung von 2-(2,2-disubstituierten)-Äthylimidazolinen bei der Bekämpfung von Diabetes | |
| DE3440621A1 (de) | Pharmazeutische zusammensetzung zur bekaempfung von vireninfektionen und deren verwendung | |
| DE2502156A1 (de) | Verfahren zur thromboseverhuetung und mittel dazu | |
| CH644596A5 (de) | 2,6-dimethyl-1,4-dihydropyridin-3,5-dikarbonsaeureester und verfahren zu ihrer herstellung. | |
| DE2708327A1 (de) | Entzuendungshemmendes mittel | |
| DE69007439T2 (de) | Mittel gegen Tumore. | |
| DE68909071T2 (de) | Dialkyl-diselenide mit antineoplastischer Aktivität. | |
| DE69603617T2 (de) | Phosphorhaltige cytisin-derivate | |
| DE1795730C3 (de) | D-GIu cosaminsalze von Adenosinphosphaten und Verfahren zu ihrer Herstellung | |
| DE69427927T2 (de) | Verwendung von Trimetazidin zur Herstellung von Medikamenten für die Behandlung von Gesundheitsstörungen, die durch die Nephrotoxizität von Cyclosporin A bedingt sind. | |
| DE2314387A1 (de) | Arzneimittel zur behandlung boesartiger neubildungen, vorzugsweise von haemoblastosen und chorionepitheliom | |
| DE1695043C2 (de) | Pharmazeutische Zusammensetzungen mit sedativen und tranquillisierenden Eigenschaften | |
| DE69218461T2 (de) | Pharmazeutische mischung mit antineoplastischer wirksamkeit | |
| DE2645873C3 (de) | Ajmalinderivate und ein Verfahren zu deren Herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |